{"url_path":"/sec/avtx/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1534120/0001534120-26-000033-index.html","accession_number":"0001534120-26-000033","cik":"0001534120","ticker":"AVTX","issuer_name":"Avalo Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1534120/0001534120-26-000033-index.html","primary_entity_key":"0001534120","primary_entity_name":"Avalo Therapeutics, Inc."},"word_count":44,"has_tables":true,"body_markdown":"Item 1. Legal Proceedings.\n\nThe information set forth in Note 11 - Commitments and Contingencies, under the heading “Litigation” to our unaudited condensed consolidated financial statements, included in Part I, Item 1 of this Quarterly Report on Form 10-Q, is incorporated herein by reference."}